Prognosis in antiphospholipid syndrome.
The results of prospective large cohort studies of patients with different clinical subsets of APS have been reported recently. A significant impact of the disease on long-term survival has been documented in these studies. Cumulative irreversible damage secondary to thrombosis results in organ dysfunction and morbidity. To assess prognosis and treatment in APS, it is imperative to quantify damage. We have recently created and validated an Antiphospholipid Damage Index, which is currently undergoing improvements. Having APS, whether primary or secondary, definitely confers a poor prognosis.
Amigo
M C
MC
Department of Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City, Mexico. mary_carmenamigo@hotmail.com
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000032:analysis; D017152:Antibodies, Antiphospholipid / Q000032:analysis* / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D015415:Biomarkers / Q000032:analysis; D005260:Female; D005313:Fetal Death; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000473:pathology; D009017:Morbidity; D011247:Pregnancy; D011248:Pregnancy Complications; D011379:Prognosis; D012008:Recurrence; D012720:Severity of Illness Index; D013927:Thrombosis / Q000209:etiology* / Q000473:pathology
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D015415:Biomarkers